Considering that neo-angiogenesis plays a pivotal role in tumor growth, and that TRAIL-based drugs including SRH-DR5-B-iRGD are cytotoxic both towards tumor and endothelial cells, the anti-angiogenic role of SRH-DR5-B-iRGD is difficult to differentiate from its antitumor activity. The gene discussed is TNFSF10; the disease is neoplasm.